Insider Faiz Buys 5,000 Shares at $100, Reinforcing Confidence as INHIBRX Biosciences Skirts 52‑Week Low

Insider Buying Continues in a Volatile Market

In a week when the Nasdaq‑listed biopharma has traded below its 52‑week low, Kayyem Jon Faiz, a key board member and long‑time insider, added 5,000 shares to his holdings on September 16. The purchase, executed at $100 per share, increased his net position to roughly 429,360 shares—about 0.23 % of the company’s outstanding equity. This move comes a day after the stock closed at $101.77 and follows a broader pattern of incremental buying by the Faiz family trusts.

What Does the Latest Deal Signal for Investors?

The transaction is modest in dollar terms, yet its timing is notable. The company’s share price has fallen 6 % in the past week and the broader healthcare sector remains under pressure. By buying at a discount to recent highs, Faiz appears to be reinforcing his confidence in the company’s pipeline and management team, signaling that he expects the stock to recover its momentum. For investors, the buy can be interpreted as a positive endorsement of the company’s strategic direction, especially when paired with the simultaneous large‑block purchases by CEO Mark Lappe and the relatively quiet trading activity by other directors.

A Profile of Kayyem Jon Faiz

Faiz has a long history of disciplined insider activity. In 2025, he sold 90,000 shares and purchased 15,000 option‑granted shares, reflecting a balanced approach to liquidity and equity retention. More recently, he has consistently bought 5,000‑share blocks at prices ranging from $100 to $113, indicating a preference for incremental, market‑aligned purchases rather than large‑scale acquisitions. His holdings are largely held through family trusts and custodial accounts for his children, a common structure that limits the impact of a single transaction on public perception. Overall, Faiz’s pattern shows a steady, long‑term commitment to the company with periodic buying to support share price stability.

Implications for the Company’s Future

The cumulative insider activity—Faiz’s latest purchase, Lappe’s 25,000‑share block, and a series of smaller sales by Kimberly Manhard—suggests a balanced ecosystem of confidence and liquidity management. While the stock remains volatile, the insiders’ willingness to add equity indicates that they view the company’s future prospects favorably. For the broader shareholder base, this insider buying can be a catalyst for renewed interest, particularly if the company’s upcoming clinical data releases or regulatory milestones deliver positive results. Investors should watch for any changes in the insiders’ holdings, as further accumulation could provide a bullish signal, whereas significant sales might trigger caution.